Show simple item record

dc.contributor.authorMillat-Martínez, P.
dc.contributor.authorIla, R.
dc.contributor.authorLaman, M.
dc.contributor.authorRobinson, L.
dc.contributor.authorKarunajeewa, H.
dc.contributor.authorAbel, H.
dc.contributor.authorPulai, K.
dc.contributor.authorSanz, S.
dc.contributor.authorManning, L.
dc.contributor.authorMoore, Brioni
dc.contributor.authorBassat, Q.
dc.contributor.authorMitjà, O.
dc.identifier.citationMillat-Martínez, P. and Ila, R. and Laman, M. and Robinson, L. and Karunajeewa, H. and Abel, H. and Pulai, K. et al. 2018. Electrocardiographic safety of repeated monthly dihydroartemisinin-piperaquine as a candidate for mass drug administration. Antimicrobial Agents and Chemotherapy.

BACKGROUND: Mass drug administration (MDA) of sequential rounds of antimalarial drugs is being considered as a tool for malaria elimination. As an effective and long-acting antimalarial, Dihydroartemisinin-piperaquine (DHA/PQP) appears suitable as a candidate for MDA. However, absence of cardiac safety data following repeated administration hinders its use in the extended schedules proposed for MDA. METHODS: We conducted an interventional study in Lihir Island, Papua New Guinea, with healthy individuals aged 3 to 60 years who received a standard 3-day course of DHA/PQP on 3 consecutive months. Twelve-lead electrocardiography (ECG) readings were conducted pre-dose and 4h after the final dose of each month. The primary safety endpoint was QTc (using Fridericia's correction; QTcF) prolongation from baseline to 4h post-dosing. We compared the difference in prolongation between the third course post-dose and the first course post-dose. RESULTS: Of 84 enrolled participants, 69 (82%) completed all treatment courses and ECG measurements. The average increase in QTcF was 19.6 ms (SD 17.8) and 17.1 ms (SD 17.1) for the first-course and third-course post-dosing ECGs [risk difference -2.4 (95%CI - 6.9 to 2.1), p=0.285], respectively. We recorded QTcF prolongation >60 ms from baseline in 3 (4.3%) and 2 (2.9%) participants after the first course and third course (p=1.00), respectively. No participants had QTcF intervals >500 ms at any time point. CONCLUSIONS: Three consecutive monthly courses of DHA/PQP were as safe as a single course. The absence of cumulative cardiotoxicity with repeated dosing support the use of monthly DHA/PQP as part of malaria elimination strategies.

dc.publisherAmerican Society for Microbiology
dc.titleElectrocardiographic safety of repeated monthly dihydroartemisinin-piperaquine as a candidate for mass drug administration
dc.typeJournal Article
dcterms.source.titleAntimicrobial Agents and Chemotherapy
curtin.departmentSchool of Pharmacy and Biomedical Sciences
curtin.accessStatusFulltext not available

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record